Investigators at Nagoya University have engineered a novel CAR-T cell therapy directed against Eva1, a protein overexpressed in various solid tumors including lung, pancreatic, and liver cancers. This next-generation approach improves immune synapse formation and T-cell activation, overcoming prior challenges in solid tumor immunotherapy. Detailed molecular engineering of CAR spacers and intracellular domains enhances antitumor efficacy, positioning this treatment as a promising candidate for difficult-to-treat malignancies.